Skip To Main Content
Rajen Mody on Muck Rack

Rajen Mody

Ann Arbor
As seen in: Wiley Online Library, JAMA Network, The Lancet, Cell Reports Medicine, Pediatrics, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rajen

Contact Rajen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Race and Ethnicity and Overall Survival in Pediatric Acute Myeloid Leukemia

|
By Daniel J. Zheng, Long Quynh Khuong, Catherine Aftandilian, Kira Bona, Emi Caywood, Caitlin Elgarten, Brian Fisher, Cody-Aaron L Gathers, Taumoha Ghosh, M. Monica Gramatges, Gary Hettinger, Meret Henry, Yuan-shung V. Huang, Yimei Li, Kelly W. Maloney, Tamara Miller, Rajen Mody, Regina M. Myers, Haley Newman, Jose Ortiz, Alix E. Seif, Caroline Smith, Jamie Stokke, Naomi J. Winick, Jennifer Wilkes, Victor Wong, Richard Aplenc, Kelly Getz, Amir Mian, Arunkumar Modi
| JAMA Network Verified
Race and Ethnicity and Overall Survival in Pediatric Acute Myeloid Leukemia Supplement 1. eTable 1. Definitions of Organ-Specific ICU Utilization for the Operationalization of Acuity at Presentation and Severe Frontline Organ Toxicity Variables eFigure 1. Consort Diagram eFigure 2. Cumulative Hazard of Relapse by Race and Ethnicity eTable 2. Association Between Cardiovascular, Respiratory, and Renal Presentation Acuity and OS eFigure 3.
Open in Who Shared Issue with article?

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study

|
By Benjamin J. Lerman, Madeleine King, Rajen Mody
| Wiley Online Library Verified
ALK anaplastic lymphoma kinase CI confidence interval COG Children's Oncology Group CR complete response GM-CSF granulocyte-macrophage colony-stimulating factor HRNB high-risk neuroblastoma I/T/DIN irinotecan/temozolomide/dinutuximab INPC International Neuroblastoma Pathology Classification INRC International Neuroblastoma Response Criteria IQR interquartile range MR minor response NFE not fully evaluated OR objective response ORR objective response rate OS overall survival PD progressive...
Open in Who Shared Issue with article?

Chromosomal instability degrades developmental phenotypes essential for anti-GD2 immunotherapy outcomes in high-risk neuroblastoma

|
By Ryan Rebernick, Jae Choi, Noshad Hosseini, Jin Zhou, Yu Ning, Rui Wang, Xuhong Cao, Meredith Irwin, Yi-Mi Wu, Chandan Kumar, Raja Rabah, Rochelle Bagatell, Arul M. Chinnaiyan, Rajen Mody, Marcin Cieslik, Calvin Hesse, Alec Chu
| Cell Reports Medicine Verified
Assessment of outcome on treatment regimens containing anti-GD2 immunotherapy Clinical information from University of Michigan patients’ charts was obtained between 05/2012 and 06/2023. For every patient information on length of follow up, overall survival, mortality, treatment regimens, and time to progression on each treatment regimen was collected.
Open in Who Shared Issue with article?
See all 14 articles